{"entity":{"id":"checkmate-205","kind":"trial","name":"CheckMate 205","aka":[],"tldr":"Established PD-1 blockade in relapsed Hodgkin lymphoma with ~70% response rates and seeded the frontline nivolumab-AVD idea.","summary":"CheckMate 205, trial NCT02181738 sponsored by Bristol Myers Squibb and reported in 2016, established PD-1 blockade with nivolumab in relapsed or refractory classical Hodgkin lymphoma after autologous transplant, with responses in about seventy percent of patients, and seeded the frontline nivolumab-AVD idea. Across 243 patients in cohorts A to C the response rate was 69 percent with complete responses in 16 percent and durable progression-free intervals, leading to accelerated approval in May 2016, while cohort D tested nivolumab-AVD in the frontline with very high complete response rates, the basis for SWOG S1826. OnCo links it to Hodgkin lymphoma, nivolumab and the pairing of PD-1 blockade with AVD chemotherapy. Whether PD-1 blockade can replace chemotherapy entirely in some patients is the question its cohort D opened.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT02181738","url":"https://clinicaltrials.gov/study/NCT02181738"}],"tags":[],"related":[],"cancers":["hodgkin-lymphoma","relapsed-refractory-hodgkin-lymphoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02181738","phase":"2","setting":"Relapsed/refractory classical Hodgkin lymphoma after autologous transplant: nivolumab (cohorts A-C); cohort D nivolumab-AVD frontline","sponsor":"BMS","result":"ORR 69%.","started":"2014-08-12","startedType":"actual","yearReported":2016,"enrolled":243,"enrolledBasis":"registry","outcomes":[{"endpoint":"Objective response rate","primary":true,"unit":"%","arms":[{"name":"Nivolumab","n":243,"value":69}],"source":"https://doi.org/10.1200/JCO.2017.76.0793"}]},"route":"/trials/checkmate-205/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"pairing":[{"id":"pd1-plus-avd-hodgkin","kind":"pairing","name":"PD-1 blockade + AVD chemotherapy","route":"/pairings/pd1-plus-avd-hodgkin/"}],"paper":[{"id":"paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018","kind":"paper","name":"CheckMate 205: nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous transplant failure, extended follow-up","route":"/key-papers/paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018/"},{"id":"paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016","kind":"paper","name":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","route":"/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016/"}]}}